|
Board
of Directors
Kenneth
B. Lee, Jr., Chairman
Mr. Lee has served as a director since September 2003
and as Chairman of the Board since February 2005. He has also served
as a member of our Compensation Committee and Chairman of our Audit
Committee since 2003, and serves as our Audit Committee Financial
Expert. He served as a member of the Corporate Governance Committee
from February 2005 to June 2005 and as our Vice-Chairman of the
Board from March 2004 to January 2005. Mr. Lee has over 30 years
of experience with technology-based companies. He is a former Ernst
& Young Partner, where he was employed for 29 years, and was
instrumental in the founding and successful development of the Ernst
& Young life science practice in the San Francisco Bay Area.
Mr. Lee is currently a General Partner with Hatteras Venture Partners,
LLC (formerly, BioVista Capital, LLC), which he joined in 2003.
Prior to that, he served as President of A.M. Pappas & Associates,
LLC, a venture capital concern. He serves on the boards of two other
public companies: CV Therapeutics, Inc. and POZEN Inc. During his
tenure with Ernst & Young, he co-founded the National Conference
on Biotechnology Ventures, the International Strategic Partnering
Conference and the Palo Alto Center for Strategic Transactions.
Mr. Lee received a Bachelor of Arts degree from Lenoir-Rhyne College
and an M.B.A. from the University of North Carolina at Chapel Hill.
Kip
A. Frey
Mr. Frey has served as a director since June 2002, is a member of
our Audit Committee and the Chairman of our Corporate Governance
Committee since 2002. Since 2001, he has been a Partner with Intersouth
Partners, one of the oldest and largest venture capital firms in
the southeast. Mr. Frey is also currently an adjunct professor at
Duke University, where he has taught since 1998. He served as 2001-2002
Chairman of the Council for Entrepreneurial Development in Research
Triangle Park, N.C. Mr. Frey was the Vice President and General
Manager of Dynamic Commerce Applications for Siebel Systems from
2000 until 2001. Between 1998 and 2000, he served as the President
and Chief Executive Officer of OpenSite Technologies, Inc., a software
company acquired by Siebel Systems in May 2000. Over the past five
years, Mr. Frey has been the leader and architect of three of Research
Triangle Park’s most notable entrepreneurial ventures, Ventana
Communications Group, Accipiter, Inc. and OpenSite Technologies,
Inc. He is a member of the board of directors of the Triangle Community
Foundation, Durham Academy and several local civic and charitable
organizations. In 1999, Digital South Magazine named him the Southeast’s
top CEO. Mr. Frey is a Phi Beta Kappa graduate of the University
of Southern California Film School and of Duke Law School.
Nancy
J. Hutson, Ph.D.
Dr. Hutson has served as a director since October 2006
and is a member of our Compensation Committee. Dr. Hutson retired
from Pfizer, Inc., where she spent 25 years in various research
and leadership positions, most recently serving as Senior Vice President,
Global Research and Development and Director of Pfizer's largest
pharmaceutical R&D site, known as Groton New London Laboratories.
In January 2006, she was awarded a Women of Innovation award by
the Connecticut Technology Council for research innovation and leadership
for her work at Pfizer's Groton New London Laboratories, where she
led 4,500 scientists and managed a budget in excess of $1 billion.
While at Pfizer, Dr. Hutson was an active member of numerous committees,
serving as Chair of the Groton New London Laboratories Leadership
Team and the Exploratory Development Strategy Team, and as a member
of the Worldwide Development Operations Group, Senior Leadership
Team and the Pharmaceuticals Steering Committee, among others. She
was also a sponsor of the Network of Executive Women where she served
as a mentor for senior women at Pfizer Global Research & Development.
Dr. Hutson has served on various community boards, including the
African Medical and Research Foundation, the University of Connecticut
Health Science Center, and the Connecticut Business & Industry
Association. She has authored or co-authored more than 45 academic
research papers and abstracts. Dr. Hutson received her B.A. in General
Biology from Illinois Wesleyan University and her Ph.D. in Physiology
and Biochemistry from Vanderbilt University. She completed a post-doctoral
fellowship at the Diabetes and Endocrinology Center at Vanderbilt
and a postdoctoral fellowship in the Department of Clinical Biochemistry
at the University of Oxford.
Richard
S. Kent, M.D.
Dr. Kent has served as a director since June 2004, is
a member of our Corporate Governance Committee and has been the
Chairman of our Compensation Committee since September 2004. Since
2002, Dr. Kent has also served as the President and Chief Executive
Officer of Serenex, Inc. and served as President and Chief Executive
Officer of Ardent Pharmaceuticals, Inc. from 2001 until joining
Serenex. In total, Dr. Kent has more than 20 years of global pharmaceutical
experience, including serving as Senior Vice President, Global Medical
Affairs, and Chief Medical Officer of GlaxoSmithKline. Prior to
GlaxoSmithKline, Dr. Kent held senior positions at Glaxo Wellcome
Inc. and Burroughs Wellcome Co. At Glaxo Wellcome, he was Vice President,
U.S. Medical Affairs and Group Medical Director, from 1998 through
2001, in addition to serving on the board of directors of Glaxo
Wellcome and other senior level operating committees responsible
for directing the development and commercialization of the company’s
products. Prior to such time, at Burroughs Wellcome, he was International
Director of Medical Research. Dr. Kent has supervised dozens of
Investigational New Drug Applications and over 20 successful New
Drug Applications (and equivalent submissions in Europe and the
rest of the world) in a wide range of therapeutic areas including
CNS, Antivirals, HIV, Respiratory, Gastrointestinal, Anesthesia/Critical
Care, Cardiovascular, and Oncology. Dr. Kent received his undergraduate
degree from the University of California, Berkeley and his medical
degree from the University of California, San Diego. He completed
his medical training at Harvard (Peter Bent Brigham Hospital), Stanford
University Medical Center and Duke University Medical Center, and
was a member of Duke University’s medical faculty. He is board
certified in both internal medicine and cardiology.
Jonathan
S. Leff 
Mr. Leff has served as a director since July 2007 and is a member
of the Corporate Governance Committee. Mr. Leff is a Managing Director
at Warburg Pincus, a private equity firm managing more than $20
billion in private equity assets. He joined the firm in 1996. He
is responsible for the firm's investment efforts in biotechnology
and pharmaceuticals. He received an A.B. in Government from Harvard
College and an MBA from the Stanford University Graduate School
of Business. Prior to joining Warburg Pincus, he was a consultant
at Oliver, Wyman & Co. He is a director of Allos Therapeutics,
Altus Pharmaceuticals, InterMune, Neurogen Corporation, Sunesis
Pharmaceuticals and ZymoGenetics.
Christy
L. Shaffer, Ph.D., President & Chief Executive Officer
Inspire Pharmaceuticals, Inc.
Dr. Shaffer is a seasoned pharmaceutical executive and Ph.D. scientist
with extensive experience in directing complex drug development
processes for innovative products. She joined Inspire as the first
full-time employee from Burroughs Wellcome in 1995 as Director of
Clinical and was appointed rapidly to VP of Development, Chief Operating
Officer and, in 1998, President and Chief Executive Officer and
Board member. Under Dr. Shaffer's tenure, Inspire became a publicly
traded company in 2000, raising $76 million, and has completed five
subsequent equity financings, raising an additional $354 million,
which includes a $75 million investment by Warburg Pincus in 2007.
Dr. Shaffer has received many notable awards including the YWCA
Academy of Women 2007 Award in Science and Technology, the Charles
& Colvard Women of Brilliant Achievement™ award, the Council
for Entrepreneurial Development (CED) Award for Entrepreneurial
Excellence in 2004 and Business Woman of the Year in NC 2003, 2004,
by the Business Advisory Council in Washington, DC. Under Dr. Shaffer's
leadership, Inspire was named one of The Scientist's Best
Places to Work in Industry three times, one of Business North
Carolina's Best Employers in North Carolina and received numerous
Best Places to Work Awards for employers in Research Triangle Park.
In 2008 alone, Inspire was recognized by the American Heart Association
and Business Leader magazine/Rex Healthcare as one of the
healthiest companies in the Triangle. Dr. Shaffer serves on the
Biotechnology Industry Organization (BIO) Board and the BIO Emerging
Companies Section Governing Body, the Foundation Board of Directors
of the North Carolina Museum of Art, the Kresge Science Advisory
Board for Meredith College, the NC School of Math and Science Foundation
Board and Board of Directors for Clinipace, a privately held clinical
research software company in RTP. Dr. Shaffer served as Chair of
the CED, which is the oldest and largest organization of its kind
in the US, and was a past Board member of the North Carolina Biotechnology
Center. Dr. Shaffer received a B.S. in Biology/Chemistry and a Ph.D.
in Pharmacology from the University of Tennessee.
Page
last updated: 01-Jul-2008
|
|
|
|
|
|
Copyright
© 1999-2005 Inspire Pharmaceuticals Inc. All rights reserved
|
|
|
|
